A prognostic signature to predict outcome in ovarian cancer patients

Applications: Ovarian cancer prognosis, ovarian cancer patient stratification

The Oxford Classic enables accurate prediction of ovarian cancer prognosis via the identification of the “EMT-high” subtype gene signature. This will help identify new treatment options for poor outcome cancers and assist in the stratification of patients into promising new clinical trials.

The graph is from Cancer Cell paper Volume 37, Issue 2, 10 February 2020, Pages 226-242.e7

Features	Benefits
Discovered that the “EMT-high” subtype is associated with poor treatment response and low survival rate Uses “EMT-high” subtype for accurate prediction of patient ovarian cancer outcome	First to link tumour subtypes to cell-of-origin subtypes in ovarian cancer Novel, innovative technology
Successfully identified a group of poor prognosis patients in 8 independent published studies	Proven to be effective in a clinical setting Proves to be a reliable gene signature
Potential for use in stratifying patients for promising cancer therapies	Patients can avoid painful, unnecessary surgeries once prognosis is detected by Oxford Classic Identifies patients eligible for early inclusion in clinical trials targeting EMT
Able to help build patient relevant models of EMT using organoids to guide drug discovery	Encourages the development of new personalised therapies for the Oxford Classic-defined “EMT-high” subtype Provides a method of testing efficacy of new drugs in patients

Request more information
about this technology

Back to Technologies Available

Technologies for License

A prognostic signature to predict outcome in ovarian cancer patients

Ready to get in touch?